This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: ?-synuclein, Parkinson’s disease, Silica-based topical delivery, sustained release, drug delivery, blood brain barrier delivery, bispecific antibody, neurodegenerative disease, peptide-based drug delivery, biomacromolecules, cerebral malformations, cavernous malformations, neurodegenerative diseases, Alzheimer’s disease, brain tumor, cancer, chemoproteomics, proteome, apoptosis, autophagy, fibrosis, cardioprotection, heart attack, drug discovery, small molecules, agentic AI, real-world patient data, clinical research, drug development, federated learning, protein engineering, generative AI, synthetic biology, organoid, oncology, immune-oncology, organoid screening, drug screening, in-silico models, multi-scale foundation models, GLP-1, obesity, CAR-T cell therapy, tumor, axonal degeneration, tissue bioprinting, regeneration, hypophosphatasia, neutrophil, macrophage, inflammation, glycol-therapeutics, hyperphosphatemia